Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lyell Immunopharma, Inc. - Common Stock (NQ:LYEL)

16.47 -0.26 (-1.55%)
Streaming Delayed Price Updated: 11:07 AM EDT, May 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lyell Immunopharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Lyell Immunopharma Targets 2027 FDA Filing as CAR-T Pipeline Advances ↗
Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely outlined the company’s clinical development priorities, regulatory strategy and manufacturing plans during a Stifel investor session... 
Via MarketBeat
News headline image
Lyell Immunopharma Announces Participation in May Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business Officer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in March Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Lyell Immunopharma Announces Initiation of Patient Dosing in First-of-Its-Kind Phase 3 Head-To-Head CAR T-Cell Clinical Trial in Aggressive Large B-Cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
Issued on behalf of GT Biopharma, Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares ↗
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
This United Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
News headline image
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Participation in September Investor Conferences
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Inc (NASDAQ:LYEL) Reports Q2 2025 Earnings Beat with Clinical Progress on LYL314 ↗
Lyell Immunopharma reports Q2 2025 with a narrower loss than expected, driven by cost controls. Clinical progress for CAR T-cell therapy LYL314 remains strong, with pivotal trials advancing. Cash... 
Via Chartmill
Topics Earnings
News headline image
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Applied Materials To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Lyell Immunopharma to Participate in the H.C. Wainwright “HCW@Home” Series
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Announces Positive New Clinical Data Demonstrating High Rates of Durable Complete Responses from the Phase 1/2 Trial of LYL314 for the Treatment of Aggressive Large B-cell Lymphoma
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
From Lyell Immunopharma, Inc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Here are the top movers in Thursday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
Lyell Immunopharma to Participate in the Goldman Sachs Global Healthcare Conference
From Lyell Immunopharma, Inc
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.